ZYXI - Premarket analyst action - healthcare

Fate Therapeutics (FATE) initiated with a Buy at BofA Securities. PT set to $115, implies a 33% increase from last price.Wedbush analyst David Nierengarten downgraded FATE to Neutral from Outperform as it sees “higher downside risk”and less reward as clinical programs advance and start being compared to standards of care. PT set to $88.Fate Therapeutics reported Q4 earnings on Feb. 24 that trailed EPS estimates but topped sales forecast.Editas Medicine (EDIT) downgraded to Hold from Buy at Truist; PT set to $45. "Lack of clarity compounded by recent leadership turnover give us reason to pause," wrote Truist Securities analyst Joon Lee.The analyst pointed to slow enrollment for a study of EDIT-101 in a rare genetic eye disease known as LCA10 as well as the “inherent noise involved in subjective visual assessments.”SAGE Therapeutics (SAGE) downgraded to Neutral from Buy at Mizuho; PT set to $81. Yesterday, H.C. Wainwright reiterated its Neutral

For further details see:

Premarket analyst action - healthcare